NASDAQ
23.10.25 | 22:00
8,950 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | H.C. Wainwright reaffirms Buy rating on Fulcrum Therapeutics stock at $12 | 2 | Investing.com | ||
| FULCRUM THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.10. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 | 1 | GlobeNewswire (USA) | ||
| 10.10. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 93 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen | |
| 08.10. | Leerink Partners raises Fulcrum Therapeutics stock price target to $16 on SCD drug potential | 1 | Investing.com | ||
| 01.10. | Oppenheimer reiterates Outperform on Fulcrum Therapeutics stock ahead of data | 8 | Investing.com | ||
| 12.09. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 123 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen | |
| 09.09. | Fulcrum Therapeutics: Vielversprechende Studiendaten zu Sichelzell-Medikament Posiradir | 1 | Investing.com Deutsch | ||
| 04.09. | Fulcrum Therapeutics auf der Cantor Global Healthcare Conference: Neue Hoffnung bei Sichelzellanämie | - | Investing.com Deutsch | ||
| 28.08. | Fulcrum Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.08. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present at Upcoming Investor Meetings | 1 | GlobeNewswire (USA) | ||
| 08.08. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 134 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen | |
| 30.07. | RBC Capital hebt Kursziel für Fulcrum Therapeutics auf 5 US-Dollar an | 1 | Investing.com Deutsch | ||
| 29.07. | H.C. Wainwright upgrades Fulcrum Therapeutics stock rating on promising SCD data | 1 | Investing.com | ||
| 29.07. | Fulcrum Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 29.07. | Fulcrum Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.07. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 | 200 | GlobeNewswire (Europe) | - Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious... ► Artikel lesen | |
| 29.07. | Fulcrum Therapeutics GAAP EPS of -$0.28 beats by $0.01 | 1 | Seeking Alpha | ||
| 29.07. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease | 124 | GlobeNewswire (Europe) | - Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% - Evidence... ► Artikel lesen | |
| 28.07. | Fulcrum Therapeutics-Aktie schießt vor Daten zu Sichelzellkrankheit in die Höhe | 10 | Investing.com Deutsch | ||
| 28.07. | Fulcrum Therapeutics stock soars ahead of sickle cell trial data | 3 | Investing.com |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,270 | +0,49 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| CUREVAC | 4,616 | -0,30 % | PRESSESPIEGEL/Unternehmen: LEG, DEUTSCHE BAHN, FLINK, BIONTECH/CUREVAC, NEURAXPHARM | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
LEG - Der Chef des zweitgrößten deutschen Vermieters LEG, Lars von Lackum... ► Artikel lesen | |
| MODERNA | 22,675 | -2,05 % | BioNTech-Konkurrent Moderna: Studie gescheitert, Aktie unter Druck | Die Aktie von Moderna steht heute deutlich unter Druck. Grund sind Phase-3-Daten, die das Unternehmen am Mittwoch nach US-Börsenschluss veröffentlicht hat. Der Zytomegalievirus-(CMV)-Impfstoffkandidat... ► Artikel lesen | |
| VALNEVA | 4,110 | +0,49 % | Valneva-Aktie unter Druck - Anleger verlieren vorerst das Vertrauen in den Impfstoffhersteller! | ||
| AMGEN | 252,35 | -0,04 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
| NOVAVAX | 7,144 | -0,68 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| STRYKER | 330,10 | +0,09 % | What You Need to Know Ahead of Stryker's Earnings Release | ||
| BIOGEN | 128,55 | -0,50 % | Biogen Inc.: Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 | Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality... ► Artikel lesen | |
| ILLUMINA | 86,12 | +0,08 % | Roche fordert Illumina mit neuer Gen-Sequenzierung-Technologie heraus | DJ Roche fordert Illumina mit neuer Gen-Sequenzierung-Technologie heraus
Von Bill Alpert
DOW JONES--Das Gen-Sequenzierungslabor des Broad Institute hat in dieser Woche das DNA-Genom von Säuglingen... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 57,50 | -0,86 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 500,00 | +0,85 % | Regeneron Says CHMP Recommends Libtayo For EU Approval As Adjuvant Treatment Of CSCC | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,562 | -0,20 % | Sangamo Therapeutics: Die Chance ist noch nicht vom Tisch! | ||
| VIKING THERAPEUTICS | 29,185 | -0,10 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on Schedule
VK2735 Phase 1 Maintenance... ► Artikel lesen | |
| EDITAS MEDICINE | 3,137 | -0,03 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen |
Das Unternehmen FULCRUM THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 8,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FULCRUM THERAPEUTICS INC finden Sie auf Wallstreet Online.